- Analyst Steven Lichtman initiated coverage of MiniMed with a buy rating on September 8 citing an attractive valuation and a favorable share exchange structure with a 7 % discount from Medtronic.
- The transaction is expected to help MiniMed transition into an independent entity while addressing concentrated shareholdings, with Wells Fargo also maintaining a buy rating and a 26.00 USD price target.
- Despite acknowledging risks including intense competition and CMS bidding pressures, the analyst views the risk reward profile as favorable given the company's robust product pipeline and progress.
